Abstract
The early life gut microbiome has been suggested to be a potential driver of neurocognitive development. Evidence for this relationship in preterm children, who are at increased risk of both gut microbiome disruptions and neurodevelopmental impairment, is scarce. In a sample of 73 very preterm infants drawn from a prospective birth cohort, we assessed associations between the neonatal gut microbiome and neurodevelopment at 9 months and 2 years. The gut microbiome was profiled from stool samples collected prior to NICU discharge using shotgun metagenomics. By taking a consensus-based analytic approach, we found strong evidence for associations between the abundances of several gut bacterial species and measures related to autistic traits (e.g. Klebsiella spp.), socio-emotional development, including temperament (e.g. Enterobacter cloacae complex, Veillonella parvula), and executive functioning (Clostridium perfringens). The abundances of functional modules involved in gut-brain signalling, particularly those involved in histamine, tryptophan and quinolinic acid metabolism, were associated with measures related to executive functioning and cognitive-behavioural flexibility. This study provides evidence that the neonatal gut microbiome composition may affect longer-term neurodevelopmental profiles following preterm birth, particularly those related to socio-emotional development, autistic traits and executive functioning.
Competing Interest Statement
DB declares having received funding from OM Pharma for unrelated work. The other authors declare no competing interests.
Funding Statement
This research was funded in part by the Wellcome (no. 108890/Z/15/Z, 228326/Z/23/Z, 218493/Z/19/Z). For the purpose of open access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission. This work was supported by Theirworld (www.theirworld.org). K.V., A.K., L.J-S. and R.S. were supported by the Translational Neuroscience PhD Program at the University of Edinburgh, funded by Wellcome (grant numbers 108890/Z/15/Z, 228326/Z/23/Z and 218493/Z/19/Z). J.P.B. is supported by a UKRI MRC programme grant (MR/X003434/1). H.T. is a PhD student in Clinical Brain Sciences and receives funding support from Simpson Special Care Babies charity.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the principles of the Declaration of Helsinki, and ethical approval was obtained from the UK National Research Ethics Service (South East Scotland Research Ethic Committee 16/SS/0154). Informed consent was obtained from a person with parental responsibility for each participant.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
